Eli Lilly (LLY) Receives FDA Approval for Foundayo Weight Management Pill

Eli Lilly and Company (NYSE:LLY) is one of the best future stocks to buy for the next 5 years. On April 1, Eli Lilly announced the FDA approval of Foundayo (orforglipron), the first once-daily GLP-1 receptor agonist pill for chronic weight management that can be taken without food or water restrictions. Indicated for adults with obesity or overweight with weight-related comorbidities, the medication is designed to be used alongside a reduced-calorie diet and increased physical activity.

Foundayo will be available starting April 6, through LillyDirect and retail pharmacies, with a pricing structure starting at $25 per month for those with commercial insurance and $149 for self-pay patients. The approval is supported by the ATTAIN-1 clinical trial, where participants on the highest dose lost an average of 27.3 pounds (12.4%) over 72 weeks, compared to just 2.2 pounds for the placebo group.

Beyond weight reduction, the trial showed improvements in cardiovascular risk markers, such as systolic blood pressure and cholesterol levels. Unlike previous oral GLP-1 treatments, Foundayo’s small-molecule formulation allows for flexible dosing at any time of day, addressing a significant practical barrier for many patients seeking non-injectable obesity care. Eli Lilly and Company (NYSE:LLY) has already submitted orforglipron for regulatory approval in over 40 countries, aiming to expand global access to this oral treatment for both weight management and type 2 diabetes.

Eli Lilly and Company (NYSE:LLY) is a healthcare company that develops human pharmaceutical products, including cardiometabolic health, oncology, and immunology products.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None.  Follow Insider Monkey on Google News.